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L. Ron van der Wieken, MD; David De Bono, MD; Wolfgang Rutsch, MD;
Thomas F. Schaible, PhD; Harlan F. Weisman, MD; Peter Klootwijk, MD; Karin M. Nijssen;
Jeanne Stibbe, MD; Pim J. de Feyter, MD; and the European Cooperative Study Group
Background Patients with unstable angina despite intensive
medical therapy, ie, refractory angina, are at high risk for
developing thrombotic complications: myocardial infarction or
coronary occlusion during percutaneous transluminal coro-
nary angioplasty (PTCA). Chimeric 7E3 (c7E3) Fab is an
antibody fragment that blocks the platelet glycoprotein (GP)
Ib/IIIa receptor and potently inhibits platelet aggregation.
Methods and Results To evaluate whether potent platelet
inhibition could reduce these complications, 60 patients with
dynamic ST-T changes and recurrent pain despite intensive
medical therapy were randomized to c7E3 Fab or placebo.
After initial angiography had demonstrated a culprit lesion
suitable for PTCA, placebo or c7E3 Fab was administered as
0.25 mg/kg bolus injection followed by 10 ,g/min for 18 to 24
hours until 1 hour after completion of second angiography and
PTCA. During study drug infusion, ischemia occurred in 9
c7E3 Fab and 16 placebo patients (P=.06). During hospital
stay, 12 major events occurred in 7 placebo patients (23%),
including 1 death, 4 infarcts, and 7 urgent interventions. In the
T he term "unstable angina" encompasses a range
of clinical situations related to sudden worsening
of preexisting coronary disease.12 The underly-
ing pathophysiological mechanism is a dynamic process,
thought to begin with rupture of an atherosclerotic
plaque and ulceration of the plaque surface, leading to
platelet aggregation and nonocclusive or occlusive
thrombosis.3-5 In most patients, resolution of the throm-
bus and stabilization of the plaque will occur, and further
ischemic symptoms can be prevented with bed rest and
drugs that reduce myocardial oxygen consumption and
prevent thrombosis.267 In a subgroup of patients, how-
ever, ischemic episodes continue despite intensive an-
tianginal therapy, including nitrates, 13-blocking agents,
heparin, and aspirin.2 Patients with such "refractory
angina" are usually offered urgent percutaneous translu-
minal coronary angioplasty (PTCA) or coronary artery
bypass graft surgery (CABG), even though these urgent
procedures are associated with increased morbidity and
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c7E3 Fab group, only 1 event (an infarct) occurred (3%,
P=.03). Angiography showed improved TIMI flow in 4 placebo
and 6 c7E3 Fab patients and worsening of flow in 3 placebo
patients but in none of the c7E3 Fab patients. Quantitative
analysis showed significant improvement of the lesion in the
patients treated with c7E3 Fab, which was not observed in the
placebo group, although the difference between the two treat-
ment groups was not significant. Measurement of platelet
function and bleeding time demonstrated >90% blockade of
GPIIb/IIIa receptors, >90% reduction of ex vivo platelet
aggregation to ADP, and a significantly prolonged bleeding
time during c7E3 Fab infusion, without excess bleeding.
Conclusions Combined therapy with c7E3 Fab, heparin,
and aspirin appears safe. These pilot study results support the
concept that effective blockade of the platelet GPIIb/IIIa
receptors can reduce myocardial infarction and facilitate
PTCA in patients with refractory unstable angina. (Circulation.
1994;89:596-603.)
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mortality in comparison with elective PTCA or
CABG.8-10 This increased complication rate is thought to
be associated with ongoing intracoronary thrombosis.1"
Removal of platelet aggregates and thrombus in
patients with refractory angina may help to relieve acute
ischemia and to reduce the risk of urgent PTCA.
However, administration of thrombolytic drugs in pa-
tients with refractory unstable angina has not demon-
strated any beneficial effect.12-16 This ineffectiveness
may result in part from activation of platelets by these
agents.
The chimeric 7E3 (c7E3) monoclonal antibody Fab
fragment is a potent inhibitor of platelet aggregation.
The antibody inhibits aggregation by blocking the gly-
coprotein (GP) 1Ib/IIIa receptor on the platelet surface,
thereby blocking the final common pathway of platelet
activation and aggregation.17-19 In a double-blind ran-
domized placebo-controlled pilot study, the safety and
preliminary efficacy of c7E3 Fab treatment were studied
in patients with refractory unstable angina who were
undergoing PTCA. It was hypothesized that c7E3 Fab in
combination with nitrates, heparin, and aspirin would
facilitate stabilization of the culprit coronary lesion and
thus reduce recurrent ischemia during the waiting pe-
riod for PTCA and reduce the complication rate during
and after the PTCA procedure. The effect of c7E3 Fab
on the severity of the culprit coronary lesion was
assessed by quantitative angiographic analysis.
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Methods
Patient Selection
Patients between 21 and 75 years old who exhibited at least
one episode of angina with concomitant dynamic ST-T segment
changes were eligible for the study. In addition, at least one
episode of ischemia (either chest pain or ST-T changes) had to
occur despite bed rest and medical treatment with intravenous
heparin and nitrates. Coronary angiography was performed
within 24 hours after the most recent episode of ischemia.
Those patients with a single culprit lesion suitable for PTCA
were enrolled, provided that a second coronary angiogram,
followed by PTCA, could be performed 18 to 24 hours after the
first (diagnostic) angiogram. Patients were excluded if they
exhibited features of ongoing ischemia requiring immediate
intervention. Other exclusion criteria were prior PTCA of the
same coronary segment within 6 months; a previous myocardial
Q-wave infarction within 7 days; female sex with childbearing
potential; recent major trauma including resuscitation, surgery,
or gastrointestinal or genitourinary bleeding within the past 6
weeks; known hepatic or renal disorder; history of bleeding
diathesis or a platelet count of <100 000/mm3; and known
autoimmune disorders. Informed consent was obtained after
completion of the diagnostic angiogram and before protocol-
specific measures.
Medical Treatment
Patients were randomized to receive either c7E3 Fab or
placebo in a double-blind manner. c7E3 Fab was administered
as an intravenous bolus injection of 0.25 mg/kg, followed by a
continuous infusion of 10 ,g/min. Study medication was drawn
through a 0.22-,um low-protein-binding filter and administered
through an in-line 0.22-,um low-protein-binding filter, starting
within 4 hours after completion of the first coronary angio-
gram. Infusion of the study drug was to continue until 1 hour
after the completion of the PTCA procedure, which was
scheduled between 18 and 24 hours after the start of the
infusion. In patients with severe recurrent ischemia, the sec-
ond angiogram and PTCA could be performed urgently, at the
discretion of the investigator.
All patients were concomitantly treated with intravenous
nitroglycerin at a dose between 50 and 200 ,ug/min, with heparin
at a dose sufficient to achieve a prolongation of the activated
partial thromboplastin time to 2.0 to 2.5 times the control value,
and with aspirin at a minimum dose of 80 mg once a day.
Patients who were not on aspirin treatment at the start of the
study received an initial dose of 250 mg aspirin. Other medica-
tion, such as ,-blockers and calcium channel blockers, were
continued as before randomization and adjusted as required by
the clinical status.
Coronary Angiography and Angioplasty
Coronary arteriography was performed by the Judkins tech-
nique. Heparin 2500 to 5000 IU was administered at the
beginning of the procedure. Low-osmolar contrast medium
was used for all angiograms. The coronary segment responsi-
ble for the ischemia (culprit lesion) was identified from the
angiographic appearance, in combination with the location of
the ECG changes during ischemia. At least two orthogonal
projections were made of the culprit lesion, after intracoro-
nary injection of 1 to 3 mg of isosorbide dinitrate. In addition,
at least three projections of the left coronary artery and at
least two projections of the right coronary artery were filmed.
During the first and the second angiograms, the same projec-
tions and x-ray gantry setting were used. All coronary angio-
grams were centrally assessed by two observers who were
blinded with respect to treatment assignment. The following
items were visually scored: TIMI flow grade20 of the culprit
artery; presence of intracoronary thrombus, defined as an
intraluminal filling defect visible during at least one complete
cine run; and stenosis severity as visually assessed in multiple
projections. In addition, the culprit lesions were analyzed in a
quantitative manner with the computer-based Cardiovascular
Angiography Analysis System.21 Minimal lumen diameter was
calculated with the catheter tip as a scaling device. The
percent diameter stenosis was obtained by comparing the
minimal diameter value at the obstruction site with the inter-
polated reference contour in the same position. The extent of
the obstruction was determined from the diameter function on
the basis of curvature analysis and expressed in millimeters.
"Plaque area" is the difference in area in square millimeters
between the reference and detected contours over the length
of the lesion.22 Values from two orthogonal projections were
averaged.23
After the second angiogram, 10 000 IU heparin and 250 mg
aspirin were administered before the angioplasty procedure.
In case of a prolonged procedure, extra doses of 5000 IU
heparin were administered every hour during the procedure.
Primary success of angioplasty was defined as <50% residual
diameter stenosis of the culprit vessel, without signs of myo-
cardial infarction or ischemia and without urgent coronary
bypass operation or death.
ECG Monitoring
A continuous three-lead vector ECG was recorded with a
computerized system (MIDA-10004) from randomization until 4
hours after PTCA. The orthogonal leads (Frank lead system) as
well as the derived 12-lead ECG were analyzed for ST-T segment
changes by a central assessment committee without knowledge of
the treatment. Reversible ST-T changes were classified as either
ST segment elevation or depression of at least 0.1 mV, T-wave
changes (development of negative or biphasic T waves or pseu-
donormalization of preexisting T-wave abnormalities), or mini-
mal ST-T changes not fulfilling the criteria for the other catego-
ries. The MIDA-1000 system computed averaged ECG com-
plexes during 2-minute intervals after exclusion of all abnormal
beats (premature ventricular contractions, noise, etc). Thus,
ECG changes were detected only if these persisted during at least
one sample interval. Episodes of ischemia were scored in four
categories: (1) pain with concomitant ECG changes, (2) pain
without ECG changes, (3) pain without ECG recording available,
and (4) ECG changes without pain (silent ischemia). ST-T
segment changes at the time of angiography and PTCA were
excluded from assessment.
Assessment of Bleeding and Laboratory Test
All patients underwent daily clinical assessment for bleed-
ing complications and other adverse events. Bleeding events
were defined as major or minor according to the Thrombosis in
Myocardial Infarction (TIMI) Study Group criteria.25 Major
bleeds were defined as intracranial bleeding or bleeding
associated with a decrease in hemoglobin (Hb) >3.1 mmol/L
or with a hematocrit (Ht) decrease of at least 15%. Bleeding
was defined as minor if (1) it was spontaneous gross hematuria
or hematemesis; (2) blood loss was observed along with an Hb
decrease >1.9 mmol/L or an Ht decrease of at least 10%; or
(3) no bleeding site was identified despite an effort to find one
along with a decrease in Hb >2.5 mmol/L or an Ht decrease of
at least 12%. To account for transfusion, the change in Hb was
calculated as the change in Ht/3 plus the number of units of
blood transfused.26
Laboratory evaluations for hematology and cardiac en-
zymes were performed during infusion and throughout the
subsequent hospitalization. Bleeding time was measured at
baseline and just before the second angiography. Three differ-
ent methods for bleeding time were used between hospitals:
Ivy (normal, 1 to 4 minutes), Simplate (normal, <8 minutes),
or Duke (normal, 1 to 3 minutes). In a subgroup of 18 patients
in one hospital, the platelet function was studied by measuring
GPIIb/IIIa receptor blockade with an ex vivo radiometric
method using 125I-7E3 murine IgG antibody solution in Tris
buffer, supplied by Centocor,18 and by assessment of ex vivo
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platelet aggregation in response to ADP at final concentra-
tions of 2, 5, and 20 ,umol/L, respectively. Results are ex-
pressed as maximum percent aggregation achieved after 5
minutes in the test platelet-rich plasma, using platelet-poor
plasma as a reference of 100%. Measurements of platelet
function were made at baseline and 2 and 6 hours after the
start of the study drug infusion, just before the second
angiogram and after completion of PTCA, and 48 and 72 hours
after the start of the infusion.
Because of the possibility of antibody formation against c7E3
Fab, serum was sampled for human antichimeric antibodies
(HACA) at baseline, before and after PTCA, before discharge,
and again after 2, 6, and 12 weeks. Measurements of HACA
titers were performed in a central laboratory. An enzyme immu-
noassay was used in which patient sera were incubated with
biotinylated c7E3 Fab that was bound to microtiter plates via a
streptavidin linkage. The presence of HACA was measured in a
standard colorimetric assay system using horseradish peroxidase-
conjugated goat antihuman Fc and reading the resultant optical
density spectrophotometrically. An assessment of positive im-
mune response to c7E3 Fab was based on the magnitude and
specificity of assay results from postinjection samples relative to
the preinjection sample.19
Study End Points
The efficacy end points were defined as death, myocardial
infarction (as defined by creatine kinase greater than two times
the upper limit of normal), and recurrent ischemia (both
symptomatic and silent ischemia). Before data analysis, it was
decided to use a composite primary end point for statistical
analysis, including death, myocardial infarction, and recurrent
ischemia requiring urgent intervention (specifically, PTCA,
CABG, intra-aortic balloon pump, or stent implantation to
maintain coronary patency). The occurrence of all end points
was validated by a central clinical end point committee.
Secondary efficacy analyses included the occurrence of all
recurrent ischemic episodes (as described in the previous
section) and angiographic end points. Angiographic end points
included both qualitative visual assessment of changes and
quantitative differences between the first and second coronary
angiograms.
Statistical Analysis
Differences between groups were analyzed on an "intention-
to-treat" basis, with a two-tailed Student's t test for continuous
variables or Fisher's exact test for categorical variables.
Changes in quantitatively measured coronary artery stenosis,
as well as in bleeding time in each group, were compared with
a two-tailed paired t test, and differences between groups were
tested with unpaired t tests. Differences in the total numbers
of ischemic episodes were examined with the Mann-Whitney
rank sum test.
Results
Between September 1991 and July 1992, 60 patients
were enrolled in the study. Thirty patients received
c7E3 Fab, and 30 patients received placebo. Patient
enrollment was slow because many physicians appeared
to be reluctant to postpone PTCA for 24 hours after the
first angiogram. Most baseline characteristics were sim-
ilar between the groups (Table 1), but the patients in
the placebo group had a longer history of angina(P=NS) and more extensive coronary artery disease
(P< .05). The distributions of the ischemia-related ves-
sels were similar in both groups. In the c7E3 Fab group,
22 of 30 patients (73%) had their first angiogram within
12 hours after the most recent episode of ischemia; in
the placebo group, 26 patients (87%). Medication at the
time of the most recent episode of ischemia was inten-
TABLE 1. Clinical, Medical, and Angiographic
Characteristics at Baseline
Male, n
Age, y (median, range)
History of
Myocardial infarction within 7 days
Angina for more than 4 weeks
PTCA
CABG
Medication before ischemia
Heparin
Aspirin
Nitrates
Intravenous
Oral
3-Blocker
Calcium channel blocker
ECG changes during ischemia
ST elevation
ST depression
AT
Other*
Ischemia-related vessel
Left anterior descending artery
Right coronary artery
Left circumflex artery
Multivessel disease
c7E3 Fab
(n=30)
20
61, 38-73
6
8
4
26
21
24 27
4 2
22 24
15 22
8
11
9
2
13
8
5
4
16
6
8
6
14
10
6
15
PTCA indicates percutaneous transluminal coronary angio-
plasty; CABG, coronary artery bypass graft surgery.
*The ECGs before enrollment showed minimal (2 placebo and
1 c7E3 Fab) or no changes (1 placebo patient) or were not
available for review by the committee (1 patient in each group).
The difference between the incidence of multivessel disease
between the two groups was statistically signfficant (P<.05).
sive and similar in both groups (Table 1). During the
study drug infusion, all patients received intravenous
nitrates and heparin, and all but two (one in each
group) received aspirin. The ECG changes during isch-
emia before enrollment were also similar.
Recurrent Ischemia
During infusion of the study drug, ischemia occurred
in 9 patients treated with c7E3 Fab and in 16 placebo
patients (P=.06), whereas 9 and 6 patients, respectively,
developed ischemia after PTCA (Table 2). Most patients
had multiple episodes of ischemia. The total number of
patients with different types of ischemia was not different
between the two treatment groups (P=.15). Similarly, the
total number of episodes was not significantly different
between patients receiving c7E3 Fab (33 episodes) or
placebo (56 episodes, P=.17).
In 1 placebo patient, an urgent intervention was
performed because of recurrent ischemia before the
Placebo
(n=30)
24
60, 38-73
5
14
5
2
27
23
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TABLE 2. Recurrent Ischemia
c7E3 Fab Placebo
A B A B
n 30 30
Pain+ST-T changes 2 ... 5 3
Pain-ST-T changes 1 .. 2 ...
Pain, no ECG 1 1
Silent ST-T changes 5 8 12 5
Patients with pain or ST-T changes 9 9 16 6
Total No. of patients 13 18
Patients with recurrent ischemia between diagnostic and second angiography (A) or after percutaneous
transluminal coronary angiography (PTCA) until discharge (B). Multiple episodes and different types of ischemia
could occur in one patient. Episodes of ischemia during angiography or PTCA were not included.
scheduled PTCA. During the hospital stay, a total of 12
major events, defined as death (n=1), myocardial in-
farction (n=4), or urgent intervention because of severe
recurrent ischemia (n=7), occurred in 7 placebo pa-
tients, and 1 event (a myocardial infarction) occurred in
a patient treated with c7E3 Fab (Table 3; 1 versus 7
patients, P=.03). Three placebo patients experienced
more than 1 major event.
Multivessel disease was present in 5 of the 7 placebo
patients who developed an event, whereas an event oc-
curred in a c7E3 Fab-treated patient with single-vessel
disease. After correction for the imbalance in baseline
characteristics, the difference between the two groups was
not statistically significant in this pilot study (P=.16).
Qualitative and Quantitative Angiographic Data
The TIMI flow grades of the culprit artery on the
diagnostic angiogram were comparable between the two
groups (Table 4). After treatment, the flow was improved
in six patients in the c7E3 Fab group. In the placebo
group, flow improved in four and worsened in three
patients. Although slightly more thrombi were seen in
the c7E3 Fab group at baseline, the number of thrombi
was reduced by the same number in both groups.
Quantitative analysis of the ischemia-related segment
did not reveal any changes during the study period in
the placebo group (Table 4). Conversely, between the
first and second angiograms, an increase in minimal
luminal diameter and significant reductions in the per-
cent diameter stenosis, plaque area, and stenosis length
were observed in the c7E3 Fab-treated patients. Nev-
ertheless, direct comparison of the changes between the
two treatment groups failed to reach statistical signifi-
cance, which may be because of the sample size in this
pilot study.
TABLE 3. Major Events
c7E3 Fab Placebo
A B A B
n 30 30
Death ... ... ... 1*
Myocardial infarction ... 1 3*t 1
Urgent PTCA ... ... 1* 2*1
Urgent CABG ... ... ... 3tS
Stent ... ... 1 ...
Patients with event, period A or B ... 1 4 5
Total patients with event per treatment group 1 § 7
PTCA indicates percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass graft surgery.
Patients with events during study drug infusion including second angiography and PTCA (A) or after discontin-
uation of study drug until discharge (B).
One major event occurred in 1 c7E3 Fab patient 3 days after PTCA, whereas 12 events occurred in 7 placebo
patients. In the placebo group, 3 patients had multiple events.
*A 61 -year-old man died after a complicated clinical course, including two urgent PTCA procedures because of
severe recurrent ischemia and myocardial infarction. Heart failure and hypotension were treated with an intra-aortic
balloon pump and mechanical ventilation. Severe bleeding occurred at puncture sites and gastric and pulmonary
sites, for which a total of 17 IU transfusions were given. Finally, Pseudomonas sepsis and multiple organ failure
resulted in death 26 days after allocation.
tAnother patient developed myocardial infarction during PTCA followed by persistent pain, necessitating urgent
CABG.
*The third patient developed recurrent ischemia after an initially successful PTCA of the right coronary artery and
underwent repeat PTCA followed by urgent CABG.
§P=.03.
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TABLE 4. Angiographic Results (Visual Assessment)
c7E3 Fab (n=30) Placebo (n=30)
Qualitative analysis
TIMI flow
0 1 1 4 3
1 2 1 ... 2
2 10 5 7 6
3 17 23 19 20
Improved 6 4
Worsened ... 3
Thrombus present 6 3 3 1
Quantitative analysis
Diameter stenosis, % 66±9 * 62±10 66±19 65±16
Obstruction diameter, mm 0.92±0.29 0.97±0.30 0.87±0.43 0.89±0.39
Extent of obstruction, mm 7.3±2.2 * 6.9±2.1 7.2±3.4 7.3±2.9
Plaque area, mm2 8.2±3.4 * 7.1±2.5 9.1±6.8 8.5±4.0
No. of patients with different aspects of the culprit lesion before (I, first, diagnostic angiogram) or during (II,
second, pre-PTCA angiogram) administration of c7E3 Fab or placebo. The quantitative analysis is presented as
mean±SD of the measurements.
*P<.05 for paired comparison of angiogram vs 11 in each patient group. The changes between patient groups
(c7E3 Fab vs placebo) did not reach statistical significance.
Angioplasty Procedure
Angioplasty was performed in all 60 patients. In 1
patient who received c7E3 Fab, PTCA was delayed
because of a total occlusion with a large intracoronary
clot at the second angiogram. He was treated with
alteplase 50 mg intracoronary infused over 30 minutes,
followed by 50 mg intravenously over 2 hours. The next
day, the clots were partly resolved, and PTCA was
performed successfully. One other c7E3 Fab patient
with a thrombocytosis of unknown origin received al-
teplase during PTCA because of persistent thrombus
formation. PTCA was completed with success, and the
subsequent clinical course was uncomplicated. The total
success rate of the angioplasty procedure was 83% in
the c7E3 Fab group and 70% in the placebo group.
Platelet Function and Bleeding Time
Platelet function, as measured by the number of free
GPIIb/IIIa binding sites per platelet and as ex vivo
ADP-induced platelet aggregation, was studied in 18
patients, 9 in each group. The number of free receptor
binding sites hardly changed during placebo infusion,
whereas soon after the start of c7E3 Fab infusion, the
median number of free binding sites decreased to 7% of
the baseline value (Figure). Approximately 48 hours
after the end of the infusion (t=72 hours), this number
had returned to 61% of the baseline value. Platelet
aggregation showed a similar inhibition of platelet func-
tion after c7E3 Fab infusion. Two hours after the start
of the infusion, aggregation in response to 2, 5, and 20
gmol ADP was reduced to 0%, 0%, and 17% of the
baseline value, respectively, and was returned to 61%,
66%, and 77% approximately 48 hours after the end of
the infusion. In the subset of patients in whom these
measurements were obtained, no relation was observed
between the level of platelet inhibition and either
recurrent ischemia or bleeding complications. One pa-
tient who was treated with c7E3 Fab did not show a
significant inhibition of the platelet function (Figure).
Soon after the start of the study infusion, thrombocyto-
sis was discovered in this patient, with platelet counts of
957 000/mm3.
Bleeding times were measured by different methods
(Ivy, Simplate, and Duke). Seven patients had a pro-
longed bleeding time at baseline, which could be ex-
plained by measurement after start of the infusion in
two patients and concomitant aspirin use in the others.
A prolongation of bleeding time exceeding twice the
baseline value was observed in 18 of 23 patients during
infusion with c7E3 Fab and in only 3 of 27 placebo
patients (P<.001).
Complications
There were no bleeding events requiring surgical
intervention. Five patients received blood transfusions,
three in the c7E3 Fab group and two in the placebo
group. According to the TIMI criteria, major bleeding
occurred in one patient after treatment with c7E3 Fab
and in three patients after placebo treatment. Minor
bleeding was observed in one placebo patient but not in
the c7E3 Fab patients.25 Thrombocytopenia did not
occur in any patient receiving c7E3 Fab. In one placebo
patient, thrombocytopenia developed (nadir, 12 000/
,L). This finding might be related to heparin therapy,
since this was the only medication given that can induce
thrombocytopenia, although such deep thrombocytope-
nia is a rare finding during heparin therapy.
Posttreatment serum samples for the determination
of HACA responses were obtained in 29 of 30 c7E3
Fab-treated patients and in all placebo patients. The
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lb/lila platelet receptor binding sites
3
0 2 6 pro post 48 72
anglo 2 hours since start Infusion
Platelet aggregation (20 pmol ADP)
100
75
50
25
0
0 2 6 pro post 48 72
angio 2 hours since start infusion
Graphs showing platelet glycoprotein (GP) lib/lila receptor block-
ade (top) and ex vivo platelet aggregation to 20 ,umol ADP
(bottom). Values are given as median number and individual
spread of free GPIIb/l1la receptor binding sites and percentage of
aggregation. o indicates placebo patients; *, patients receiving
c7E3 Fab. Note one c7E3 patient with number of binding sites
similar to placebo. This particular patient had thrombocytosis.
pretreatment optical density measurements varied be-
tween 0 and 1.5 (n=56). One patient who received c7E3
Fab had a HACA response specific for the murine
variable region of c7E3 Fab, exceeding the pretreatment
range. Optical density values were 2.1 at 2 weeks and
2.6 at 12 weeks.
Discussion
Current treatment of patients with unstable angina
includes drugs that reduce myocardial oxygen demand,6
as well as aspirin and heparin.7,27 In patients with
recurrent episodes of ischemia despite intense combi-
nation therapy, intracoronary thrombosis is frequently
observed, particularly if angiography is performed early
after the most recent ischemic episode.28'29 In such
patients, a more potent inhibitor of platelet aggregation,
such as a blocker of the platelet GPIIb/IIIa receptor,
may facilitate lysis of the thrombus and prevent re-
thrombosis at the site of plaque rupture, thus averting
future ischemic episodes.
The present pilot study supports the concept that
treatment with c7E3 Fab in patients with refractory
unstable angina does reduce recurrent ischemic epi-
sodes and facilitates PTCA. In 30 patients treated with
placebo, 7 (23%) had a total of 12 events. In contrast,
only 1 of the 30 patients treated with c7E3 Fab had a
single event (3%, P=.03). Recurrent ischemia during
the 18 to 24 hours of treatment before PTCA was
reduced by 44% (P=.06) in patients receiving c7E3 Fab,
and the severity of the culprit lesion was improved
(Table 4). The proportion of patients with major events,
as specified in Table 3, in the placebo group was 23%,
which is comparable to the incidence of 36% in a
previous study with similar design.12 Urgent PTCA in
such patients has been associated with a 10% to 15%
complication rate.1"12A similarly high complication rate
(30%) was observed in the present placebo group.
This study was randomized and conducted in a dou-
ble-blind manner. Nevertheless, the results are not
conclusive, because the number of patients in this pilot
study is small and because an imbalance of baseline
characteristics existed in favor of the c7E3 Fab-treated
patients. In particular, the presence of multivessel dis-
ease was more frequent (P<.05), and more patients had
previous angina (P=NS) in the placebo group. Further-
more, it cannot be excluded that the investigators
became aware of the actual treatment in some patients
because of prolonged bleeding times measured during
c7E3 Fab therapy. However, final assessment of events,
ECG recordings, and angiograms was done centrally,
without knowledge of treatment assignment.
Other Patient Studies With 7E3 Antibodies
Open-label nonrandomized studies with murine (m)
7E3 F(ab')2 and 7E3 Fab also suggest that such treat-
ment may be beneficial in patients with acute coronary
syndromes. After single bolus doses of m7E3 F(ab')2 in
patients with unstable angina, anginal pain did not
occur within the first few hours while the bleeding time
was still prolonged (>10 minutes) but returned in
several patients when the bleeding time was normal-
ized.18 More recently, Kleiman et a130 reported better
coronary artery patency and a trend for fewer ischemic
events after treatment with m7E3 Fab after thrombol-
ysis, in combination with heparin and aspirin treatment,
compared with a group of patients with acute myocar-
dial infarction who did not receive m7E3 Fab. As in the
present study, administration of the antibody was well
tolerated and was not associated with a higher bleeding
risk.
In a recently presented trial of 2100 patients undergoing
"high-risk" angiography, a single bolus of c7E3 Fab did
not prevent recurrent ischemic events.31 In that trial, a
marked reduction of events was reported during and after
a bolus injection followed by 12 hours of infusion of c7E3
Fab at the same dosage as in the present pilot study. In the
present study, c7E3 Fab was administered during at least
18 hours before PTCA. One hour after PTCA, the drug
was discontinued to allow sheath removal. These two
studies indicate that prolonged (212 hours) inhibition of
platelet aggregation either before or after31 PTCA will be
necessary to prevent ischemic events in patients with
unstable coronary plaque. Additional studies are required
to assess the optimal timing and duration of therapy with
c7E3 Fab.
Degree of Platelet Function Inhibition and Safety
Extensive blockade of platelet GPIIb/IIIa receptors
and inhibition of ex vivo platelet aggregation were
demonstrated in the subgroup of c7E3 Fab-treated
patients for whom this was measured. During the infu-
sion of c7E3 Fab, approximately 90% of the platelet
GPIIb/IIIa receptors were blocked, resulting in nearly
complete inhibition of platelet function, as measured by
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ADP-induced platelet aggregation and a markedly pro-
longed bleeding time. Reversibility of the inhibition was
illustrated by partial recovery of platelet function within
48 hours after the end of the infusion (t=72 hours,
Figure). These data are in agreement with previous
open-label studies with m7E3 F(ab')2 and m7E3
Fab,1832 demonstrating that c7E3 Fab produced a po-
tent, yet reversible, inhibition of platelet function in
patients with unstable angina who are treated concom-
itantly with heparin and aspirin. Nevertheless, adminis-
tration of c7E3 Fab was well tolerated in all patients,
and no serious, severe, or life-threatening adverse
events were observed. There was no difference in the
incidence of major or minor bleeding events between
placebo-treated and c7E3 Fab-treated patients; in fact,
three placebo-treated patients had major bleeding
events by TIMI criteria,25 compared with only one c7E3
Fab-treated patient. Therefore, infusion of c7E3 Fab
up to 24 hours before and during PTCA appeared safe
in patients receiving concomitant intravenous heparin
and aspirin.
No thrombocytopenia was observed in any patients
receiving c7E3 Fab in this study. Severe thrombocytope-
nia was reported in a few patients injected with m7E3
Fab.30 Unfortunately, it remains uncertain whether this
was a true adverse drug effect or an artifact (so-called
pseudothrombocytopenia in vitro). Nevertheless, it is
reassuring that this problem did not recur after modifi-
cation of the administration procedure, including the
use of an in-line microfilter.
In the present study, as well as other c7E3 Fab
studies,32 some patients demonstrated high pretreat-
ment reactivity in the HACA assay, yet demonstrated
platelet GPIIb/IIIa receptor blockade and inhibition of
platelet aggregation in response to c7E3 Fab that was
no different from that observed in patients with low
pretreatment reactivity. The high pretreatment reactiv-
ity was also not associated with adverse events (eg,
thrombocytopenia or allergic reactions) after c7E3 Fab
injection. Only one patient exhibited posttreatment
reactivity that was greater than the observed pretreat-
ment range of responses. This finding of apparently low
immunogenicity with the humanized antibody fragment
is consistent with other trials of c7E3 Fab.32 The collec-
tive investigational experience with c7E3 indicates that
this agent has substantially less immunogenic potential
than the m7E3 Fab agent; studies with m7E3 Fab have
reported human anti-murine antibody rates as high as
50%.30 Nevertheless, the significance of both pretreat-
ment and posttreatment assay reactivities observed in
this study requires further investigation, particularly
with respect to the safety of repeated c7E3 Fab dosing.
Conclusions
This pilot study is the first randomized, placebo-
controlled study with c7E3 Fab in patients with refrac-
tory unstable angina pectoris. Despite intensive con-
comitant therapy with intravenous heparin, aspirin, and
c7E3 Fab or placebo, no excess bleeding complications
were observed. Overall, patients treated with c7E3 Fab
had a more favorable course, with less recurrent isch-
emia, some resolution of coronary stenosis, and fewer
complications compared with the placebo group. How-
ever, the series is small, and definitive assessment of the
value of c7E3 Fab must await the completion of ongoing
larger trials. Still, these data indicate that potent inhi-
bition of platelet aggregation may be of particular
clinical value in patients with refractory unstable angina
who undergo PTCA.
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